Decheng Capital LLC Nuvation Bio Inc. Transaction History
Decheng Capital LLC
- $396 Billion
- Q2 2025
A detailed history of Decheng Capital LLC transactions in Nuvation Bio Inc. stock. As of the latest transaction made, Decheng Capital LLC holds 25,954,439 shares of NUVB stock, worth $60.2 Million. This represents 12.78% of its overall portfolio holdings.
Number of Shares
25,954,439
Previous 25,954,439
-0.0%
Holding current value
$60.2 Million
Previous $45.7 Billion
10.8%
% of portfolio
12.78%
Previous 12.81%
Shares
2 transactions
Others Institutions Holding NUVB
# of Institutions
193Shares Held
168MCall Options Held
2.31MPut Options Held
221K-
Black Rock Inc. New York, NY16.2MShares$37.7 Million0.0% of portfolio
-
Vanguard Group Inc Valley Forge, PA15.9MShares$36.9 Million0.0% of portfolio
-
Omega Fund Management, LLC Boston, MA11MShares$25.6 Million46.36% of portfolio
-
Laurion Capital Management LP New York, NY10.2MShares$23.8 Million0.37% of portfolio
-
Octagon Capital Advisors LP New York, NY7.69MShares$17.8 Million5.69% of portfolio
About Nuvation Bio Inc.
- Ticker NUVB
- Exchange NYSE
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 217,244,000
- Market Cap $504M
- Description
- Nuvation Bio Inc., a clinical-stage biopharmaceutical company, focuses on the development of therapeutic candidates for oncology. The company's lead product candidate is NUV-422, a small molecule inhibitor targeting cyclin-dependent kinase (CDK)2, CDK4, and CDK6. It is also developing NUV-868, a selective oral small molecule BET inhibitor that e...